AUTHOR=Ramos German E. , Caglevic Christian , Bulnes Juan F. , Panay Sergio E. , Zapata Mario I. , Daniele Andrés J. , Rodríguez Manuel E. 

TITLE=Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=9

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1060813

DOI=10.3389/fcvm.2022.1060813

ISSN=2297-055X

ABSTRACT=<p>Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.</p>